AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01769768
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
Trial: NCT01769768
Drug: Wafarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg single dose of warfarin (oral tablet) will be given to patients.
Trial: NCT01579279
Drug: ABT-652 6 mg
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg capsules
Trial: NCT01579279
Drug: ABT-652 12 mg
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg capsules
Trial: NCT01579279
Drug: ABT-652 12 mg - 18 mg
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg - 18 mg capsules
Trial: NCT01579279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01994759
Drug: Glucocorticosteroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections).
Trial: NCT01177800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
Trial: NCT01542138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humectant placebo cream
Trial: NCT04030741
Drug: Meronem and flagyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meronem and flagy
Trial: NCT00441285
Drug: ABZ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
Trial: NCT00441285
Drug: PZQ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
Trial: NCT01533116
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01097707
Drug: LY500307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, daily for 24 weeks
Trial: NCT01097707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, daily for 24 weeks
Trial: NCT01533116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01533116
Drug: levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01533116
Drug: levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00911937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sham 4mg and 8 mg tables taken daily.
Trial: NCT02797431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
Trial: NCT00168051
Drug: Advante
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02999893
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
Trial: NCT00011752
Drug: FCWAY
RxNorm normalized name: Fenclonine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01316718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
Trial: NCT01687218
Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01687218
Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01687218
Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04083560
Drug: Vit B12
RxNorm normalized name: vit B12/pyridoxine/thiamine ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 250mcg
Trial: NCT00502567
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet once daily
Trial: NCT00502567
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT02393027
Drug: [18F] LBT-999 PET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04357444
Drug: 1: ILT101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections, once-daily administration for 10 consecutive days.
Trial: NCT04357444
Drug: 2: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in Subcutaneous route
Trial: NCT02076620
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
Trial: NCT01659853
Drug: CD07805/47 gel 0.5%/CD07805/47 Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily
Trial: NCT04938700
Drug: probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics as granules can be used for infants and adolescents
Trial: NCT04938700
Drug: conventional medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc
Trial: NCT02029872
Drug: Mupirocin calcium 2 % ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal mupirocin calcium 2% ointment
Trial: NCT00964886
Drug: desipramine hydrochloride
RxNorm normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
Trial: NCT00964886
Drug: benztropine mesylate 0.125 mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
Trial: NCT02449369
Drug: Postop oral oxycodone & acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02223351
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02084511
Drug: Placebo to BI 1026706 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to BI 1026706 solution
Trial: NCT02084511
Drug: Placebo to BI 1026706 tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to BI 1026706 tablet
Trial: NCT02084511
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib capsule
Trial: NCT03427710
Drug: CiVi007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cholesterol lowering drug
Trial: NCT00246584
Drug: SPP100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02449369
Drug: Postop acetaminophen IV
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366080
Drug: GSK189254
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00887484
Drug: BENZOYL PEROXIDE/ CLINDAMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
Trial: NCT01939314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
Trial: NCT01859988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01379378
Drug: Contigen
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-10 cc
Trial: NCT01072630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo, also in tablet form taken orally, once daily in the morning.
Trial: NCT00400725
Drug: Clobex® Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
Trial: NCT00400725
Drug: Clobex® Vehicle Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
Trial: NCT00400725
Drug: Clobex® Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
Trial: NCT03914638
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, three times daily
Trial: NCT02755818
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
Trial: NCT00001145
Drug: Bacteriophage
RxNorm normalized name: bacteriophages
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00225823
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01908192
Drug: NaBen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
Trial: NCT01908192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
Trial: NCT04411160
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
Trial: NCT02217475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally once daily and taken every morning with food.
Trial: NCT01044017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01044017
Drug: RO4998452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral doses
Trial: NCT00728897
Drug: GSK598809 new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
Trial: NCT00728897
Drug: GSK598809 old formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
Trial: NCT02141022
Drug: Gileyna
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02703259
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02703259
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00130494
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02311231
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
Trial: NCT04308863
Drug: Chitosan scaffold/ MTA pulp dressing material
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
Trial: NCT04308863
Drug: MTA pulp dressing material
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
Trial: NCT02485067
Drug: Placebo(For THVD-201)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02485067
Drug: Placebo(For Detrusitol 2mg tablet)
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00759824
Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
Trial: NCT00890643
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02892942
Drug: Gonal-F®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 to 450 IU/d; from day 2 of menstrual cycle onward
Trial: NCT02892942
Drug: Cetrotide®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/day, starting on day 6 of Gonal-F®.
Trial: NCT02892942
Drug: Cetrotide®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
Trial: NCT00625547
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
Trial: NCT02818725
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2
Trial: NCT02605655
Drug: AMP-1915
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
Trial: NCT01992601
Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.
Trial: NCT00313625
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01604889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00289861
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01060098
Drug: anti-TNF therapy (etanercept or adalimumab)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological DMARD
Trial: NCT01466101
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo
Trial: NCT01376232
Drug: GSK1278863 + food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Fat meal + 100 mg GSK1278863
Trial: NCT03428282
Drug: Anesthesia
RxNorm normalized name: anesthesia tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
Trial: NCT01269515
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg QD
Trial: NCT01719419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
Trial: NCT02689856
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream alone
Trial: NCT02689856
Drug: Hydrocortisone acetate
RxNorm normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hydrocortisone alone
Trial: NCT03085654
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration of placebo 24 international units per dose.
Trial: NCT01942590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00720590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of placebo for 4 weeks
Trial: NCT03767582
Drug: CCR2/CCR5 dual antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
Trial: NCT00144599
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00483535
Drug: GW273225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW273225 will be available as 25 milligram tablets.
Trial: NCT02230891
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
Trial: NCT01259947
Drug: Lippia alba (Mill.) N. E. Brown ethanolic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 drops per kilogram per day, PO, twice a day
Trial: NCT02259920
Drug: KUC 7483 CL, immediate release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00513019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT00453791
Drug: GW805858
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
Trial: NCT00453791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI will be given to the subjects.
Trial: NCT00467350
Drug: milk and molasses enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
Trial: NCT03279809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case with placebo medication for 6 months after stenting
Trial: NCT02531295
Drug: Euphorbia kansui extract powder prepared as tea
RxNorm normalized name: Euphorbia kansui whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
Trial: NCT04554043
Drug: SHR7280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment
Trial: NCT04554043
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blank control
Trial: NCT02104843
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01728311
Drug: BAY1082439
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
Trial: NCT01887886
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV every 3 weeks
Trial: NCT02739555
Drug: Acide Zoledronique
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04879953
Drug: Systemic chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy